Validation of the Qualified Air System in the Pharmaceutical Industry

The present study describes the ten-year (2014–2024) validation of a Class 100,000ISO 8 qualified air system used in the manufacture of non-sterile pharmaceutical dosage forms in a GMP-certified facility. The lifecycle evaluation included design, installation, qualification, continuous operation, environmental monitoring, cleaning and disinfection verification, and annual third-party validation. The system was assessed for critical parameters, including air renewal rates, airflow directionality, the integrity of high-efficiency particulate air (HEPA) filters and ultra-low penetration air (ULPA) filters, environmental recovery times, and non-viable particle counts. Particle monitoring focused on 0.5 μm and 1.0 μm channels within the 0.5–5 μm range specified by ISO 14644-1 for ISO 8 areas. The 0.5–1.0 μm range was prioritized because it provides higher statistical representativeness for evaluating filter performance and controlling fine particulate dispersion, which is particularly relevant in non-sterile pharmaceutical production, while larger particles (>5 μm) are more critical in aseptic processes. The influence of personnel and air exchange rates on cleanliness was also assessed during the final years of the study. Results demonstrate that continuous, systematic validation ensures the controlled environmental conditions required for pharmaceutical production and supports the sustained quality and safety of the finished products. This study provides a technical reference for engineers, pharmacists, and quality professionals involved in cleanroom design, qualification, and regulatory compliance.